ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2261

Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013

Patompong Ungprasert1,2, Cynthia S. Crowson3, Eva M. Carmona Porquera4 and Eric L. Matteson5, 1Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 2Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Epidemiologic methods, outcomes and sarcoidosis, Pulmonary Involvement

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Long-term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013

 

Background/Purpose: A hallmark of sarcoidosis is lung disease, which has variable expression. This study was undertaken to better understand the course of pulmonary sarcoidosis.

Methods: A cohort of 311 incident cases of pulmonary sarcoidosis in a geographically well-defined population from 1976-2013 was identified from the comprehensive medical record-linkage system. Diagnosis of sarcoidosis required physician diagnosis supported by biopsy showing non-caseating granuloma, radiographic evidence of intrathoracic sarcoidosis and compatible clinical presentations without evidence of other granulomatous diseases.  Medical records of the confirmed cases were reviewed from diagnosis to last follow-up.  Data on stage of pulmonary sarcoidosis at diagnosis, serial pulmonary function tests (total lung capacity [TLC], force vital capacity [FVC], forced expiratory volume in 1 second [FEV1] and diffusing capacity for carbon monoxide [DLCO]), requirement of oxygen therapy and treatment were abstracted. The cumulative incidence of chronic respiratory impairment (defined as FVC of <50%, DLCO of <40% or requirement to use oxygen supplementation) adjusted for the competing risk of death was estimated.  Cox models were used to assess the association of stage of pulmonary sarcoidosis and treatment on the development of chronic respiratory impairment.

Results: The means of PFT measures at baseline in this cohort were 97.1%, 95.3%, 91.4% and 91.1% of predicted values for TLC, FVC, FEV1 and DLCO, respectively.  At 5 years, the mean percentage predicted for TLC, FVC, FEV1 and DLCO declined by 1.6%, 3.5%, 4.3% and 3.1%, respectively.  A total of 25 patients developed chronic respiratory impairment which corresponded to 10 year event rate of 4.4% (95% confidence interval [CI], 1.9%–6.9%) as demonstrated in figure 1. Stage of pulmonary sarcoidosis at diagnosis was a strong predictor for chronic respiratory impairment with hazard ratio (HR) compared with stage I of 5.29 (95% CI, 1.65–16.96) for stage II and 8.36 (95% CI, 26.3–26.52) for stage III and IV.  Use of glucocorticoids and immunosuppressive agents was associated with a significantly increased risk of chronic respiratory impairment (HR 4.60; 95% CI, 1.94–10.88 and HR 5.13; 95% CI, 1.47–17.86, respectively).  However, it is unlikely that treatment with glucocorticoids/ immunosuppressive agents had a deteriorative effect on pulmonary function.  It is more likely that use of these medications is simply an indicator of more severe disease.

Conclusion: Patients with pulmonary sarcoidosis have a good pulmonary prognosis with a low incidence of chronic respiratory impairment.

Figure 1: Cumulative incidence of chronic respiratory impairment among 311 patients with pulmonary sarcoidosis

 


Disclosure: P. Ungprasert, None; C. S. Crowson, None; E. M. Carmona Porquera, None; E. L. Matteson, None.

To cite this abstract in AMA style:

Ungprasert P, Crowson CS, Carmona Porquera EM, Matteson EL. Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/long-term-outcome-of-pulmonary-sarcoidosis-a-population-based-cohort-study-from-1976-2013/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcome-of-pulmonary-sarcoidosis-a-population-based-cohort-study-from-1976-2013/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences